# Revlimid in Patients With Acute Myelogenous Leukemia and Myelodysplastic Syndrome

> **NCT00360672** · PHASE2 · COMPLETED · sponsor: **M.D. Anderson Cancer Center** · enrollment: 27 (actual)

## Conditions studied

- Acute Myelogenous Leukemia
- Myelodysplastic Syndrome

## Interventions

- **DRUG:** Revlimid

## Key facts

- **NCT ID:** NCT00360672
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-01
- **Primary completion:** 2012-05
- **Final completion:** 2012-05
- **Target enrollment:** 27 (ACTUAL)
- **Last updated:** 2013-08-14

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00360672

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00360672, "Revlimid in Patients With Acute Myelogenous Leukemia and Myelodysplastic Syndrome". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00360672. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*